JPRN-jRCT2080222174未知1 期
A phase 1 study of K-912, nonrandomized, open label, dose escalation study in Japanese patients with solid tumors.
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with histologically or cytologically diagnosis of solid tumor
- •Patients with solid tumor which is resistant to standard anti-tumor therapies, or which no appropriate treatment is available
- •Patients with adequate organ functions
- •Patients with 0 to 1 of ECOG Performance Status (P.S.) score
- •Patients with 12 weeks or more life expectancy
排除标准
- •Patients with the severe complication
- •Patients with brain metastasis accompanying clinical symptoms
- •Patients with hematopoietic tumor
- •Patients with active infections in need of treatment for systemic
研究者
相似试验
进行中（未招募）
1 期
The purpose of this study is to evaluate the steady state pharmacokinetics and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination (FDC) in HIV-1 infected, virologically suppressed pregnant women in their second and third trimesters.Human Immunodeficiency Virus (HIV-1) InfectionsMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2021-001073-23-Outside-EU/EEAGilead Sciences, Inc.
已完成
1 期
A Phase I/Ib, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid TumorsSolid TumorsJPRN-jRCT2080225114ovartis Pharma. K.K.145
进行中（未招募）
1 期
A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa-2a and Ribavirin to Patients with Chronic Hepatitis C Infection after Participation in Other MK-7009 Clinical Trials. - Phase II Open Label Study of MK-7009Hepatitis C VirusMedDRA version: 12.0Level: LLTClassification code 10019751Term: Hepatitis C virusEUCTR2009-013053-15-BEMerck Sharp & Dohme (Europe) Inc.160
进行中（未招募）
不适用
A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical TrialsHepatitis C virusMedDRA version: 9.1Level: LLTClassification code 10019751Term: Hepatitis C virusEUCTR2009-013053-15-SEMerck Sharp & Dohme (Sweden) AB80
进行中（未招募）
不适用
A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical TrialsEUCTR2009-013053-15-PLMerck & Co., Inc.730